0001479290-22-000015.txt : 20220204 0001479290-22-000015.hdr.sgml : 20220204 20220204203534 ACCESSION NUMBER: 0001479290-22-000015 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220202 FILED AS OF DATE: 20220204 DATE AS OF CHANGE: 20220204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Foley Mark J CENTRAL INDEX KEY: 0001529196 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 22595259 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wf-form4_164402491298660.xml FORM 4 X0306 4 2022-02-02 0 0001479290 Revance Therapeutics, Inc. RVNC 0001529196 Foley Mark J C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, 20TH FLOOR NASHVILLE TN 37203 1 1 0 0 CEO Employee Stock Option (Right to Buy) 13.08 2022-02-02 4 A 0 143354 0 A 2032-02-01 Common Stock 143354.0 143354 D The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2022, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. /s/ Terri McDowell, Attorney-in-Fact 2022-02-04 EX-24 2 ex-24.htm FOLEY POA 2022

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of
(i)    Gabrielle Sims White, (ii) Dwight Moxie, and (iii) Terri McDowell, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorneys-in-fact to:

(1)    prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

(2)    execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or holder of 10% or more of a class of securities of Revance Therapeutics,  Inc.  (the  "Company"),  Forms 3,  4,  and  5  in  accordance  with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3)    do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(4)    take any other action of any type whatsoever in connection with the foregoing which, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as each such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company or Cooley LLP.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this         day of    , 2021.
12/15/2021

/s/Mark J. Foley